Company intelligence / Profile preview

iOmics Lifesciences

Cambridge, Massachusetts, United Statesen.mgi-tech.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company’s AI-driven platforms have been validated through collaborations with academic medical centers to identify novel biomarkers and drug targets—e.g., rapid identification of proteins implicated in cognitive decline with retrospective laboratory confirmation.

Therapeutic areas: OncologyCardiovascularNeurologyInfectious Diseases
Modalities: Small moleculeBiologicData science/AI platform for in silico drug discovery
Industry: Drug Discovery Services

Partnerships

Collaborations with NIH-funded academic medical centers/universities since at least 2014Corporate partners in chemical/materials safety screening projects

Beyond the preview

Go deeper on iOmics Lifesciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iOmics Lifesciences.

Explore the full profile